title: Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
abstract: BACKGROUND
  The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy.
  
  
  METHODS
  Among eight FASG trials, 3577 assessable patients were analyzed retrospectively: 2553 received epirubicin, 662 received hormonotherapy alone and 362 had no systemic treatment. Chemotherapy was FEC regimen in 86% of cases (fluorouracil, epirubicin, cyclophosphamide). Epirubicin cumulative dose was < 300 mg/m2 in 1040 patients, 300-600 in 1155, > or = 600 in 279, followed by radiotherapy in 96% of cases.
  
  
  RESULTS
  Twenty delayed LVD occurred: two in E- patients and 18 in E+ patients. In E+ patients, 14 patients normalized their cardiac function or did not require further investigations, one patient was stabilized with specific treatment, two patients worsened their functions and one died of congestive heart failure. The 7-year risk of LVD was 1.36% (95% CI 0.85-1.87) in E+ patients and 0.21% (95%CI: 0.00-0.52) in E- patients (P = 0.004). Two significant risk factors were identified: age > or = 65 years and body mass index > 27 kg/m2.
  
  
  CONCLUSIONS
  After a long-term follow-up, epirubicin-related LVD risk was acceptable (1.36%) with one toxic death (0.04%). In 78% of cases, LVD were transient or well controlled.
authors.affiliation: Centre Georges-François Leclerc, Dijon, France. pfumoleau@dijon.fnclcc.fr
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
authors.forename: H
authors.initials: H
authors.lastname: Roché
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: J
authors.initials: J
authors.lastname: Bonneterre
authors.forename: P
authors.initials: P
authors.lastname: Romestaing
authors.forename: P
authors.initials: P
authors.lastname: Fargeot
authors.forename: M
authors.initials: M
authors.lastname: Namer
authors.forename: A
authors.initials: A
authors.lastname: Monnier
authors.forename: P
authors.initials: P
authors.lastname: Montcuquet
authors.forename: M-J
authors.initials: MJ
authors.lastname: Goudier
authors.forename: E
authors.initials: E
authors.lastname: Luporsi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects*; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced
chemical_list: D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil